Besides leishmaniasis, TLR4 activation during immunotherapy has been linked to better prognosis against several infectious diseases and cancer models (Karmakar et al., 2012; Kaczanowska et al., 2013; Rostamian and Niknam, 2017). The gene discussed is TLR4; the disease is leishmaniasis.